Headwinds loom for pharma web strategy
Dominic Tyer
APRIL 11, 2024
Online changes pose some pressing questions for the industry and demand a new approach to websites and data
Sat.Apr 06, 2024 - Fri.Apr 12, 2024
130 
Number of ongoing US drug shortages reaches new high, pharmacist group says
Fierce Pharma
APRIL 11, 2024
As lawmakers, biopharma companies and others try to stabilize vulnerable pharma supply chains, drug shortages have become about as bad as they’ve ever been in the U.S. | The American Society of Health-System Pharmacists has released new data showing there were 323 drugs in shortage in the U.S. as of 2024’s first quarter—the highest number recorded since ASHP began tracking shortage data back in 2001.
Join 8,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Why So Many Nurses Are Fleeing Healthcare — And How Hospitals Can Address The Problem
MedCity News
APRIL 10, 2024
Nurse managers being too busy to train and support their team members is one of the biggest reasons nurses are exiting the healthcare industry, according to a new report. The post Why So Many Nurses Are Fleeing Healthcare — And How Hospitals Can Address The Problem appeared first on MedCity News.
EMA Says No Evidence for Link between Type 2 Diabetes Drugs and Suicidal Tendencies
PharmaTech
APRIL 12, 2024
The agency’s risk assessment committee has concluded that available evidence has not been found that supports a causal association between glucagon-like peptide-1 receptor agonists and self-harming thoughts and actions.
AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
The 7 Ps of Marketing
Healthcare Success
APRIL 8, 2024
As an engineering undergrad, I took a Marketing 101 class on a lark, seeking to better understand the psychology behind consumer behavior and developing products with a competitive edge. On the first day of class, we learned the fundamental concept of the 4 Ps of marketing. However, today, I like to use an expanded “7 Ps” definition. In any event, this marketing mix remains essential for any successful marketing strategy.
AstraZeneca, Daiichi Sankyo's Enhertu wins historic HER2 tumor-agnostic FDA nod
Fierce Pharma
APRIL 8, 2024
With Enhertu at the heart of AstraZeneca and Daiichi Sankyo’s respective goals for oncology growth, the partners have significantly expanded the antibody-drug conjugate’s (ADC's) reach in the U.S.< | With Enhertu at the heart of AstraZeneca and Daiichi Sankyo’s respective goals for oncology growth, the partners have significantly expanded the antibody-drug conjugate’s reach in the United States.
Sign up to get articles personalized to your interests!
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
More Trending
FDA Releases Guidance on Data Integrity for In Vivo Bioavailability and Bioequivalence Studies
PharmaTech
APRIL 11, 2024
The draft guidance provides recommendations for data integrity for clinical and bioanalytical portions of bioavailability and bioequivalence studies submitted with drug applications.
NHS trust bids to take license for abandoned gene therapy
pharmaphorum
APRIL 9, 2024
Great Ormond Street Hospital is applying for the license to a gene therapy for rare disease ADA-SCID that was abandoned by a biotech developer on commercial grounds.
FDA commissioner tells lawmakers his agency needs more authority to prevent drug shortages
Fierce Pharma
APRIL 11, 2024
After investigations into the FDA’s response to severe drug shortages and other issues, the House Committee on Oversight and Accountability finally had its long-awaited chance to grill the agency’s | FDA Commissioner Robert Califf, M.D., told lawmakers that the agency, as the "referee," needs to be given more authority in order to preemptively halt drug shortages.
4 Lessons We Learned From The Change Healthcare Cyberattack
MedCity News
APRIL 7, 2024
Healthcare industry leaders think there is much to learn from the Change Healthcare cyberattack, and they hope the sector can apply these lessons to prevent a hack like this from ever happening again. Overall, the chaotic aftermath of the attack underscores the dire need for a more unified approach to cybersecurity within the healthcare sector. The post 4 Lessons We Learned From The Change Healthcare Cyberattack appeared first on MedCity News.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Next-gen menopause treatments have blockbuster potential. Can women, doctors and payers be convinced?
PharmaVoice
APRIL 8, 2024
The market is huge, but will companies overcome the triple hurdles of payer hesitance, prescriber reluctance and sluggish consumer demand?
UK calls time-out on post-Brexit rules opposed by industry
pharmaphorum
APRIL 10, 2024
The UK has agreed to delay border checks on products used in life sciences R&D and manufacturing, says industry group BIA.
Regeneron hit with DOJ complaint that it hid 'hundreds of millions' in Eylea credit card processing fees from Medicare
Fierce Pharma
APRIL 11, 2024
The U.S. government is accusing Regeneron of deliberately using an unusual method to overcharge Medicare for the company’s popular eye drug Eylea. | The U.S. government is accusing Regeneron of deliberately using an unusual method to overcharge Medicare for the company’s popular eye drug Eylea.
How Can Healthcare Ensure Responsible AI Use?
MedCity News
APRIL 9, 2024
At a recent conference, executives from across the industry shared their thoughts on how the healthcare sector can ensure its use of AI is ethical and responsible. They highlighted the need for collaboration, trust building and pragmatic thinking. The post How Can Healthcare Ensure Responsible AI Use? appeared first on MedCity News.
Unlocking growth: How GenAI can help pharma companies convert new clients
PharmaVoice
APRIL 8, 2024
GenAI is profoundly reshaping various facets of the pharmaceutical industry. Projections indicate that the global GenAI market in pharma will soar to USD 2258.1 million by 2032.
Patent expiration to drive biosimilars market expansion to 2032
European Pharmaceutical Review
APRIL 11, 2024
Expirations of biologic patents has enabled manufacturers to enter the market and offer lower-cost alternatives of these drugs, [which has] resulted in increased competition and price pressure, driving the growth of the biosimilar market” A report published by Towards Healthcare has estimated that the global biosimilar market will value $1,26,019.67 million by 2032, at 17.6 percent CAGR between 2023 and 2032.
Amid corporate restructuring, Novartis plots 680 layoffs in development group
Fierce Pharma
APRIL 9, 2024
Even as Novartis rolls ahead with a global restructuring campaign targeting thousands of job cuts, the Swiss drug giant has blueprinted several hundred layoffs in its development organizational uni | Even as Novartis rolls ahead with a global restructuring campaign targeting thousands of job cuts, the Swiss drug giant has blueprinted several hundred layoffs in its development organizational unit.
AHA Urges Labor Department to Investigate MultiPlan’s ‘Unconscionable Practices’
MedCity News
APRIL 11, 2024
Following an extensive investigative report from the New York Times, the AHA is calling for the Labor Department to probe into the business practices of data analytics firm MultiPlan. The report revealed that MultiPlan works with major payers to negotiate reduced reimbursements for out-of-network medical providers — and this that practice ends up costing patients and employers.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Ed Schoonveld Discusses Drug Pricing in the US and Upcoming Articles
Pharmaceutical Commerce
APRIL 8, 2024
In an interview with Pharma Commerce Editor Nicholas Saraceno, Ed Schoonveld, Value & Access Advisor, Schoonveld Advisory, offers his thoughts on lower drug prices in the US and provides a sneak peak into future PC features.
Is the pharmaceutical sector realising its potential for sustainable manufacturing?
European Pharmaceutical Review
APRIL 11, 2024
The pharmaceutical industry is becoming increasingly conscious of emissions and the importance of sustainable manufacturing. Globally, the pharmaceutical sector emitted around 52 megatonnes of CO 2 in 2015, the most recent period for which detailed numbers are available. 1 That’s more than the automotive sector, which released 46.4 megatonnes in the same year, and the increased demand and complexity of medicines since then will only have swollen this figure. 1 Every major pharmaceutical manufact
'Most' cancer meds approved under FDA's accelerated pathway couldn't prove survival benefit after 5 years: study
Fierce Pharma
APRIL 8, 2024
One hallmark of the FDA's accelerated approval pathway is the requirement that medicines prove their benefits in confirmatory trials. | Many cancer meds approved under the FDA's accelerated approval pathway from 2013 to 2017 didn't improve overall survival after more than five years of follow-up research, the study found.
Pelago Unveils Contingency Management Program To Support Those With Substance Use Disorder
MedCity News
APRIL 9, 2024
Pelago’s new contingency management program rewards patients for engaging in treatment, such as completing a survey, completing app check-ins, attending appointments and completing cognitive behavioral therapy exercises. The post Pelago Unveils Contingency Management Program To Support Those With Substance Use Disorder appeared first on MedCity News.
How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Women want to participate in clinical trials. Lack of flexibility is still a problem.
PharmaVoice
APRIL 8, 2024
Underrepresentation of women in clinical trials affects the resulting drugs that are available down the line. Encouraging more women to partake is a critical step in promoting more equitable healthcare.
How Efficient Logistics Can Change the Lives of Rare Disease Patients
Pharmaceutical Commerce
APRIL 10, 2024
If manufacturers cannot ensure safe, cost-effective delivery of treatments for rare diseases, access will remain a challenges for many patients living with these conditions.
FDA advisers back new endpoint for myeloma approvals, paving way for faster introduction of new drugs
Fierce Pharma
APRIL 12, 2024
After oncology experts reviewed arguments in favor of a surrogate endpoint to support multiple myeloma drug approvals, drug developers may soon have a new pathway in the R&D journey. | After oncology experts reviewed arguments in favor of a surrogate endpoint to support multiple myeloma drug approvals, drug developers may soon have a new pathway in the R&D journey.
Why Hospitals Are Condemning CMS’ Proposed Inpatient Payment Rule
MedCity News
APRIL 12, 2024
CMS released a proposed rule this week that would boost hospitals’ inpatient payment rates by 2.6%. Hospitals groups have swiftly denounced this plan, arguing that this payment update is insufficient and will jeopardize hospitals’ financial stability. The post Why Hospitals Are Condemning CMS’ Proposed Inpatient Payment Rule appeared first on MedCity News.
How to Stay Competitive in the Evolving State of Martech
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
CRISPR technologies fuelling haematological innovations
European Pharmaceutical Review
APRIL 12, 2024
There has been a “notable” rise in licensing agreements for innovator drugs incorporating clustered regularly interspaced short palindromic repeats (CRISPR)-based technology for gene therapies over the past five years, according to data and analytics firm GlobalData. These agreements have amassed a total deal value of $21 billion. Of note, between 2020 to 2022, there was a “remarkable surge” in deal worth.
Ionis, Arrowhead hail data with triglyceride drugs at ACC
pharmaphorum
APRIL 8, 2024
Drugs from Ionis and Arrowhead Pharma that block apolipoprotein C-III (apoC-III) have shown their value in treating diseases associated with elevated triglyceride levels in two studies presented at the American College of Cardiology annual congress. The two companies are racing to bring their apoC-III inhibitors to market for severe hypertriglyceridaemia (HTG) and ultra-rare disorder familial chylomicronaemia syndrome (FCS).
FDA swats away Supernus’ Parkinson’s disease infusion pump for 3rd time
Fierce Pharma
APRIL 8, 2024
The third time is decidedly not the charm for Supernus and its Parkinson’s disease infusion pump. | The FDA refused to accept Supernus' first approval bid after the company acquired the med in 2020. The following year, the agency doled out a complete response letter, dashing Supernus' second try.
4 Things Digital Health Investors Look for in a Tight Funding Environment
MedCity News
APRIL 7, 2024
There are four things that entrepreneurs need to demonstrate to investors to have fundraising success: a large total addressable market, strong unit economics and product-market fit, a world-class team, and a compelling plan for the future. The post 4 Things Digital Health Investors Look for in a Tight Funding Environment appeared first on MedCity News.
Let's personalize your content